Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Ovid Therapeutics Inc
OVID
Healthcare
Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other...
neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:OVID)
New Post
View:
Posts & Comments
Threaded Posts
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Sep 25, 2019 2:49pm
still holding this stock
it would be nice to have $5 to $6 per share for me,so glta shareholders.
(83)
•••
Biomed4077
X
View Profile
View Bullboard History
Post by
Biomed4077
on Sep 24, 2019 9:40pm
Get ready for $ 12 US
https://seekingalpha.com/news/3501176-ovid-7-percent-positive-soticlestat-data
New PEA Indicates an Ultra Low-Cost Uranium Project with Huge Exploration Upside
posted Apr 26, 2024 9:00am by
Blue Sky Uranium Corp
-
|
This PEA reaffirms that the deposit is a leading low-cost uranium-vanadium project. We believe that this resurgent uranium market has a strong long-term outlook and we are therefore preparing to complete a prefeasibility study as soon as possible ...read more
(83)
•••
Biomed4077
X
View Profile
View Bullboard History
Post by
Biomed4077
on Sep 24, 2019 9:38pm
Get ready for $12 US
https://www.empr.com/home/mpr-first-report/aan-2019-coverage/ov101-gaboxadol-beneficial-in-adolescents-and-adults-with-angelman-syndrome/
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Apr 26, 2019 2:03pm
still cheap at these prices
will add more next week,probably at the end of the month.
(668)
•••
coolfooldumbguy
X
View Profile
View Bullboard History
Post by
coolfooldumbguy
on Apr 23, 2019 10:49am
it's a buy today for me
at these low prices,so glta.
(0)
•••
Tiffany
X
View Profile
View Bullboard History
Post by
Tiffany
on Apr 23, 2019 10:36am
Lots of things going on un the next few weeks
cheers
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update